Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

David Liu; Elizabeth R. Plimack; Jean Hoffman-Censits; Levi A. Garraway; Joaquim Bellmunt; Eliezer Van Allen; Jonathan E. Rosenberg

doi:10.1001/jamaoncol.2016.1056

Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

David Liu
, Elizabeth R. Plimack
, Jean Hoffman-Censits
, Levi A. Garraway
, Joaquim Bellmunt
, Eliezer Van Allen
, Jonathan E. Rosenberg

Dana-Farber Cancer Institute
Thomas Jefferson University
Massachusetts Institute of Technology
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Letter › peer-review

239 Scopus citations

Original language	English
Pages (from-to)	1094-1096
Number of pages	3
Journal	JAMA Oncology
Volume	2
Issue number	8
DOIs	https://doi.org/10.1001/jamaoncol.2016.1056
State	Published - Aug 2016

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carcinoma, Transitional Cell/drug therapy
Cohort Studies
Humans
Muscle, Smooth/pathology
Neoadjuvant Therapy
Neoplasm Invasiveness
Prognosis
Reproducibility of Results
Treatment Outcome
Urinary Bladder Neoplasms/drug therapy
Xeroderma Pigmentosum Group D Protein/genetics

Access to Document

10.1001/jamaoncol.2016.1056

Cite this

@article{59f793ea4f554083882eae3c5e27b83b,

title = "Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Transitional Cell/drug therapy, Cohort Studies, Humans, Muscle, Smooth/pathology, Neoadjuvant Therapy, Neoplasm Invasiveness, Prognosis, Reproducibility of Results, Treatment Outcome, Urinary Bladder Neoplasms/drug therapy, Xeroderma Pigmentosum Group D Protein/genetics",

author = "David Liu and Plimack, \{Elizabeth R.\} and Jean Hoffman-Censits and Garraway, \{Levi A.\} and Joaquim Bellmunt and Allen, \{Eliezer Van\} and Rosenberg, \{Jonathan E.\}",

year = "2016",

month = aug,

doi = "10.1001/jamaoncol.2016.1056",

language = "English",

volume = "2",

pages = "1094--1096",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

AU - Liu, David

AU - Plimack, Elizabeth R.

AU - Hoffman-Censits, Jean

AU - Garraway, Levi A.

AU - Bellmunt, Joaquim

AU - Allen, Eliezer Van

AU - Rosenberg, Jonathan E.

PY - 2016/8

Y1 - 2016/8

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Carcinoma, Transitional Cell/drug therapy

KW - Cohort Studies

KW - Humans

KW - Muscle, Smooth/pathology

KW - Neoadjuvant Therapy

KW - Neoplasm Invasiveness

KW - Prognosis

KW - Reproducibility of Results

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms/drug therapy

KW - Xeroderma Pigmentosum Group D Protein/genetics

UR - https://www.scopus.com/pages/publications/85016513285

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000383704700025&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1001/jamaoncol.2016.1056

DO - 10.1001/jamaoncol.2016.1056

M3 - Letter

C2 - 27310333

SN - 2374-2437

VL - 2

SP - 1094

EP - 1096

JO - JAMA Oncology

JF - JAMA Oncology

IS - 8

ER -

Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

Keywords

Access to Document

Other files and links

Fingerprint

Cite this